Alternative approaches to vaccine delivery

Human Vaccines

Volumn 6, Issue 1, 2010, Pages

  Wang, Lina ^a   Ma, Charles ^a   Coppel, Ross L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Intranasal immunization; Oral immunization; Plasmodium; Transgenic animal; Transgenic plant; Vaccine delivery; Vaccine production

Indexed keywords

MALARIA VACCINE; VACCINE;

BIOSAFETY; DISEASE TRANSMISSION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENDEMIC DISEASE; HUMAN; IMMUNOGENICITY; MALARIA; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; TRANSGENIC ANIMAL; TRANSGENIC PLANT; VACCINE PRODUCTION; BIOSYNTHESIS; METHODOLOGY; VACCINATION;

HUMANS; VACCINATION; VACCINES;

EID: 85046915322     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.1.9878     Document Type: Review

References (82)

1. Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003; 206:3803-8.
2. Vanbuskirk KM, O'Neill MT, De La Vega P, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 2009.
3. D malaria vaccine in infants. N Engl J Med 2008; 359:2533-44.
4. E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-32.
5. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995; 171:1576-85.
6. A for malaria. Expert Rev Vaccines 2006; 5:611-5.
7. A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411-20.
8. A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366:2012-8.
9. Malkin E, Hu J, Li Z, et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008; 26:6864-73.
10. A. PLoS ONE 2009; 4:5254.
11. Coppel RL. Vaccinating with the genome: a Sisyphean task? Trends Parasitol 2009; 25:205-12.
12. Ma JK, Barros E, Bock R, et al. Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep 2005; 6:593-9.
13. Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 2005; 10:185-218.
14. Rybicki EP. Plant-produced vaccines: promise and reality. Drug Discov Today 2009; 14:16-24.
15. Pujol M, Ramirez NI, Ayala M, et al. An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purification. Vaccine 2005; 23:1833-7.
16. Chowdhury K, Bagasra O. An edible vaccine for malaria using transgenic tomatoes of varying sizes, shapes and colors to carry different antigens. Med Hypotheses 2007; 68:22-30.
17. Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill LK. Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology 1995; 13:53-7.
18. 19), a potential malaria vaccine candidate, in tobacco. Plant Science 2002; 162:335-43.
19. Kedzierski L, Black CG, Coppel RL. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect Immun 2000; 68:6034-7.
20. Wang L, Kedzierski L, Wesselingh SL, Coppel RL. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect Immun 2003; 71:2356-64.
21. Wang L, Goschnick MW, Coppel RL. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge. Infect Immun 2004; 72:6172-5.
22. Wang L, Webster DE, Campbell AE, Dry IB, Wesselingh SL, Coppel RL. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Int J Parasitol 2008; 38:103-10.
23. Daniell H. Production of biopharmaceuticals and vaccines in plants via the chloroplast genome. Biotechnol J 2006; 1:1071-9.
24. Gleba Y, Klimyuk V, Marillonnet S. Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol 2007; 18:134-41.
25. Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y. In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci USA 2004; 101:6852-7.
26. Gils M, Kandzia R, Marillonnet S, Klimyuk V, Gleba Y. High-yield production of authentic human growth hormone using a plant virus-based expression system. Plant Biotechnol J 2005; 3:613-20.
27. Golovkin M, Spitsin S, Andrianov V, et al. Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci USA 2007; 104:6864-9.
28. Huang Z, Santi L, LePore K, Kilbourne J, Arntzen CJ, Mason HS. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 2006; 24:2506-13.
29. Santi L, Batchelor L, Huang Z, et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008; 26:1846-54.
30. Santi L, Giritch A, Roy CJ, et al. Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci USA 2006; 103:861-6.
31. Webster DE, Wang L, Mulcair M, et al. Production and characterisation of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Plant Biotechnology Journal 2009; in press.
32. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 1992; 89:11745-9.
33. Houdebine LM. Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis 2009; 32:107-21.
34. Schmidt C. Belated approval of first recombinant protein from animal. Nat Biotechnol 2006; 24:877.
35. Soler E, Le Saux A, Guinut F, et al. Production of two vaccinating recombinant rotavirus proteins in the milk of transgenic rabbits. Transgenic Res 2005; 14:833-44.
36. Soler E, Parez N, Passet B, et al. Recombinant rotavirus inner core proteins produced in the milk of transgenic rabbits confer a high level of protection after intrarectal delivery. Vaccine 2007; 25:6373-80.
37. Chen HL, Huang JY, Chu TW, et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008; 26:2882-9.
38. Stowers AW, Chen Lh LH, Zhang Y, et al. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci USA 2002; 99:339-44.
39. Gowda DC, Davidson EA. Protein glycosylation in the malaria parasite. Parasitol Today 1999; 15:147-52.
40. Behboodi E, Ayres SL, Memili E, et al. Health and reproductive profiles of malaria antigen-producing transgenic goats derived by somatic cell nuclear transfer. Cloning Stem Cells 2005; 7:107-18.
41. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999; 77:801-7.
42. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999; 77:789-800.
43. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58:68-89.
44. Kersten G, Hirschberg H. Needle-free vaccine delivery. Expert Opin Drug Deliv 2007; 4:459-74.
45. Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are? Expert Opin Drug Deliv 2007; 4:323-40.
46. Wang L, Coppel RL. Oral vaccine delivery: can it protect against non-mucosal pathogens? Expert Rev Vaccines 2008; 7:729-38.
47. Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002; 26:339-53.
48. Sadoff JC, Ballou WR, Baron LS, et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988; 240:336-8.
49. + cytotoxic T cells. J Exp Med 1990; 172:1083-90.
50. Flynn JL, Weiss WR, Norris KA, Seifert HS, Kumar S, So M. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol 1990; 4:2111-8.
51. Gonzalez C, Hone D, Noriega FR, et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis 1994; 169:927-31.
52. Chinchilla M, Pasetti MF, Medina-Moreno S, et al. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun 2007; 75:3769-79.
53. Ruiz-Perez F, Leon-Kempis R, Santiago-Machuca A, et al. Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL. Infect Immun 2002; 70:3611-20.
54. McKelvie ND, Khan SA, Karavolos MH, et al. Genetic detoxification of an aroA Salmonella enterica serovar Typhimurium vaccine strain does not compromise protection against virulent Salmonella and enhances the immune responses towards a protective malarial antigen. FEMS Immunol Med Microbiol 2008; 52:237-46.
55. Tartz S, Russmann H, Kamanova J, et al. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine 2008; 26:5935-43.
56. Gomez-Duarte OG, Pasetti MF, Santiago A, Sztein MB, Hoffman SL, Levine MM. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect Immun 2001; 69:1192-8.
57. Haddad D, Liljeqvist S, Kumar S, et al. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med Microbiol 1995; 12:175-86.
58. Somner EA, Ogun SA, Sinha KA, et al. Expression of disulphide-bridge- dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains. Microbiology 1999; 145:221-9.
59. Wu S, Beier M, Sztein MB, et al. Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C. J Biotechnol 2000; 83:125-35.
60. Toebe CS, Clements JD, Cardenas L, Jennings GJ, Wiser MF. Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1. Am J Trop Med Hyg 1997; 56:192-9.
61. Lewis GK. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet? Expert Rev Vaccines 2007; 6:431-40.
62. Mercenier A, Muller-Alouf H, Grangette C. Lactic acid bacteria as live vaccines. Curr Issues Mol Biol 2000; 2:17-25.
63. Moorthy G, Ramasamy R. Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls. Vaccine 2007; 25:3636-45.
64. Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 2006; 24:3900-8.
65. 19. World J Gastroenterol 2005; 11:6975-80.
66. Lavelle EC, O'Hagan DT. Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv 2006; 3:747-62.
67. Arakawa T, Komesu A, Otsuki H, et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun 2005; 73:7375-80.
68. Arakawa T, Tsuboi T, Kishimoto A, et al. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 2003; 21:3143-8.
69. Bargieri DY, Rosa DS, Lasaro MA, Ferreira LC, Soares IS, Rodrigues MM. Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route. Mem Inst Oswaldo Cruz 2007; 102:313-7.
70. 19) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol 1998; 20:413-20.
71. Carcaboso AM, Hernandez RM, Igartua M, et al. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm 2003; 260:273-82.
72. Carcaboso AM, Hernandez RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 2004; 22:1423-32.
73. Marshall VM, Silva A, Foley M, et al. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun 1997; 65:4460-7.
74. Kedzierski L, Black CG, Coppel RL. Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii. Mol Biochem Parasitol 2000; 105:137-47.
75. Blackman MJ, Ling IT, Nicholls SC, Holder AA. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol 1991; 49:29-33.
76. Kaslow DC, Quakyi IA, Syin C, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988; 333:74-6.
77. Holmgren J, Adamsson J, Anjuere F, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005; 97:181-8.
78. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004; 199:201-16.
79. Lee SE, Kim SY, Jeong BC, et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006; 74:694-702.
80. Romero JF, Ciabattini A, Guillaume P, et al. Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge. Vaccine 2009; 27:1266-71.
81. Bargieri DY, Rosa DS, Braga CJ, et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella typhimurium FliC flagellin. Vaccine 2008; 26:6132-42.
82. Stephenson I, Zambon MC, Rudin A, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80:4962-70.